Oct. 10 at 1:56 PM
$APM $2.X million upfront with up to additional
$4.X million of potential aggregate gross proceeds upon the exercise in full of warrants
NEW YORK, NY, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited(APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that it has entered into definitive agreements for the purchase and sale of 1,000,000 Class A ordinary shares at a purchase price of
$2.00 per share in a registered direct offering. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 2,000,000 Class A ordinary shares at an exercise price of
$2.00 per share that will be exercisable upon issuance and will expire twenty-four months from the effective date of a registration statement registering for resale the ordinary shares underlying the warrants. The closing of the offering is expected to occur on or about October 14, 2025
